Table 3.
Cox Proportional Hazards and Competing Risk Regressions for the Association Between suPAR and Time to Incident VTE Within 30 Days of Hospitalization
| Variable | Cox model | Fine‐Gray model | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| suPAR | ||||
| First tertile (0–5.2 ng/mL) | 1.0 (Reference) | … | 1.0 (Reference) | … |
| Second tertile (5.3–8.7 ng/mL) | 0.87 (0.48–1.58) | 0.64 | 0.88 (0.48–1.61) | 0.67 |
| Third tertile (8.8–62.7 ng/mL) | 1.52 (0.86–2.68) | 0.15 | 1.52 (0.84–2.74) | 0.17 |
| Age, per 10 y older | 0.93 (0.81–1.07) | 0.32 | 0.93 (0.81–1.07) | 0.32 |
| Men, vs women | 2.25 (1.45–3.47) | <0.001 | 2.24 (1.45–3.46) | 0.003 |
| Black, vs White, Asian, American Indian and Pacific Islander | 1.87 (1.23–2.86) | 0.004 | 1.86 (1.22–2.84) | 0.004 |
| Body mass index, per 5 kg/m2 higher | 1.06 (0.98–1.14) | 0.15 | 1.06 (0.99–1.13) | 0.12 |
| History of diabetes, vs none | 0.89 (0.58–1.37) | 0.60 | 0.90 (0.60–1.34) | 0.59 |
| History of hypertension, vs none | 0.88 (0.56–1.38) | 0.58 | 0.88 (0.55–1.41) | 0.60 |
| History of congestive heart failure, vs none | 0.57 (0.25–1.27) | 0.17 | 0.57 (0.25–1.28) | 0.17 |
| History of malignancy, vs none | 2.22 (1.13–4.36) | 0.021 | 2.21 (1.13–4.32) | 0.021 |
| Before admission anticoagulation therapy, vs none | 0.40 (0.16–1.01) | 0.053 | 0.41 (0.16–1.04) | 0.06 |
| Admission estimated glomerular filtration rate, per 5 mL/min per 1.73 m2 higher | 0.99 (0.95–1.02) | 0.39 | 0.99 (0.95–1.02) | 0.38 |
| D‐dimer, per fold higher compared with baseline | 1.44 (1.30–1.60) | <0.001 | 1.43 (0.70–1.30) | <0.001 |
HR indicates hazard ratio; suPAR, soluble urokinase plasminogen activator receptor; and VTE, venous thromboembolism.